What Researchers Did
Researchers conducted a randomized, controlled, double-blind crossover trial with long-term follow-up to evaluate the effectiveness of hyperbaric oxygen therapy for patients suffering from chronic refractory radiation proctitis.
What They Found
The study found that hyperbaric oxygen therapy significantly improved healing responses, with patients receiving HBOT showing nearly twice the improvement in SOMA-LENT scores (5.00 vs. 2.61) compared to the control group. Additionally, 88.9% of HBOT patients were responders per clinical assessment, compared to 62.5% in the control group, resulting in an absolute risk reduction of 32%.
What This Means for Canadian Patients
For Canadian patients suffering from chronic refractory radiation proctitis, this study suggests that hyperbaric oxygen therapy could be a highly effective treatment option. It offers a potential path to significantly improve healing, reduce symptoms, and enhance the quality of life for individuals experiencing this challenging side effect of radiation therapy.
Canadian Relevance
While the study authors and location are not explicitly Canadian, radiation proctitis is a recognized indication for hyperbaric oxygen therapy in Canada, making these findings relevant for Canadian patients.
Study Limitations
A limitation of this crossover design is that the initial significant differences between groups were no longer apparent after all patients received hyperbaric oxygen therapy.